Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorShanghai Tong Ren Hospital
About this trial
This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.
Eligibility criteria
Qualifiers
Subject must be at least 18 years of age and less than 80 years old
Patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for AMI and LAD should be the only culprit vessel.
Subject understand the study requirements and the treatment procedures and provided informed consent before the procedure
Disqualifiers
Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study
Known hypersensitivity or contraindication to study medications
Plan to receive revascularization in next six month.
Have received revascularization before.
Trial design
Treatments tested in this trial
- PCSK9 inhibitor （Alirocumab）plus standard medications
- standard medications
Treatment groups
20 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov